Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

This publication has 27 references indexed in Scilit:

• GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical development
  Drugs of the Future, 2001
• Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
  International Journal of Obesity, 1999
• Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasma
  European Journal of Drug Metabolism and Pharmacokinetics, 1996
• Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design
  Diabetes, 1994
• Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
  Journal of Clinical Investigation, 1994
• Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
  European Journal of Biochemistry, 1993
• Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
  Digestive Diseases and Sciences, 1993
• Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.
  Journal of Clinical Investigation, 1987
• Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
  FEBS Letters, 1987
• Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog
  Diabetes, 1980